<?xml version="1.0" encoding="UTF-8"?>
<p>There is currently no clear evidence of what therapy is efficacious to improve prognosis in patients infected with SARS-CoV-2. To date, numerous clinical trials are underway for drugs that have shown in vitro efficacy. Even less is known about the complications of COVID-19 infection and their treatment. The aim of this narrative review is to present the possible causes and pathophysiology of pulmonary fibrosis associated with COVID-19 based on the mechanisms of the immune response, in order to provide a review of the literature to suggest possible ways of prevention and treatment.</p>
